About this document
Nivolumab Administration in ccRCC Trial by Anselmo Rodrigues Dos Santos is a document available to read on EtoBox.
The CheckMate 67T trial compares subcutaneous (SC) nivolumab (NIVO) with intravenous (IV) NIVO in patients with advanced or metastatic clear cell renal cell carcinoma. Results indicate that SC NIVO demonstrates noninferiority in pharmacokinetics and objective response rates compared to IV NIVO, with a consistent safety profile and no new safety concerns. Patient-reported outcomes suggest that SC administration may enhance the treatment experience by reducing healthcare inefficiencies.
- Author
- Anselmo Rodrigues Dos Santos
- Language
- EN